Abcellera Biologics Inc ABCL

$14.82 +0.90 (6.47%)

Valuation

Market cap
4,268,025,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
9,094,899
Avg volume
6,965,202
Day's range
$14.10 – $15.00
Shares out
306,611,000
Stochastic %K
94%
Beta
1.32
Analysts
Strong Sell
Price target
$16.67

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Prat_ Sep 30, 12:37 AM
$ABCL well then
0 replies
GuslovesBio Sep 29, 11:15 PM
$ABCL JPM Initiates Coverage: Physician Survey Looks Good... https://ca.investing.com/news/stock-market-news/jpmorgan-initiates-abcellera-stock-coverage-with-overweight-rating-93CH-4858361
0 replies
desiguy Sep 29, 9:52 PM
$ABCL question is when will they be raising more money to fund their own clinical trials and extend the runway more
2 replies
Monkey7779192 Sep 29, 9:48 PM
$ABCL CEO is charismatic. Good enough for me to buy this for swing to long term hold.
0 replies
GuslovesBio Sep 29, 9:42 PM
$ABCL Do we need to set up a gofundme for Ed??
1 replies
Monkey7779192 Sep 29, 9:37 PM
$ABCL Just bought in. It seems to have good momentum and great pipeline.
0 replies
TraderinNYC Sep 29, 9:18 PM
$ABCL been holding since it was in the $5 range and I'm not selling
1 replies
Ckkung71 Sep 29, 8:40 PM
$ABCL Glory to the brave who stood up and fight then they tried to knock us down 🎩
1 replies